LA MARCA, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.789
EU - Europa 7.628
AS - Asia 5.689
SA - Sud America 539
AF - Africa 74
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 15
Totale 36.790
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.671
GB - Regno Unito 2.652
SG - Singapore 1.778
HK - Hong Kong 1.701
CN - Cina 1.281
IT - Italia 1.225
SE - Svezia 1.037
DE - Germania 714
UA - Ucraina 551
BR - Brasile 485
RU - Federazione Russa 450
TR - Turchia 365
BG - Bulgaria 237
FI - Finlandia 229
FR - Francia 119
ID - Indonesia 101
IN - India 92
CA - Canada 75
KR - Corea 60
RO - Romania 55
NL - Olanda 54
ES - Italia 50
JP - Giappone 47
IR - Iran 46
AU - Australia 39
VN - Vietnam 39
IE - Irlanda 38
MX - Messico 28
BE - Belgio 27
CZ - Repubblica Ceca 27
LT - Lituania 27
PK - Pakistan 21
IQ - Iraq 19
PH - Filippine 19
UZ - Uzbekistan 19
AT - Austria 18
PL - Polonia 18
AR - Argentina 17
NZ - Nuova Zelanda 17
BD - Bangladesh 15
CH - Svizzera 15
DZ - Algeria 14
MY - Malesia 14
TH - Thailandia 13
HR - Croazia 12
MA - Marocco 12
CO - Colombia 11
DK - Danimarca 11
EG - Egitto 11
ZA - Sudafrica 11
AL - Albania 10
LV - Lettonia 10
TW - Taiwan 10
CL - Cile 9
EU - Europa 7
KE - Kenya 7
NO - Norvegia 7
EC - Ecuador 6
GR - Grecia 6
NP - Nepal 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
IL - Israele 5
JO - Giordania 5
PT - Portogallo 5
SA - Arabia Saudita 5
SC - Seychelles 5
A2 - ???statistics.table.value.countryCode.A2??? 4
MD - Moldavia 4
PE - Perù 4
SK - Slovacchia (Repubblica Slovacca) 4
HU - Ungheria 3
NG - Nigeria 3
SI - Slovenia 3
TN - Tunisia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AZ - Azerbaigian 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LK - Sri Lanka 2
PS - Palestinian Territory 2
RS - Serbia 2
TJ - Tagikistan 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
Totale 36.773
Salva come PNG Salva come JPEG
Città #
Fairfield 3.902
Santa Clara 2.178
Ashburn 1.901
Woodbridge 1.885
Southend 1.737
Hong Kong 1.680
Houston 1.550
Seattle 1.468
Cambridge 1.303
Wilmington 1.149
Chandler 1.125
Singapore 971
Jacksonville 893
Ann Arbor 758
Dearborn 680
Nyköping 675
London 600
Modena 388
Beijing 337
San Diego 285
Princeton 237
Sofia 233
Izmir 205
Eugene 193
Moscow 172
Hefei 171
Boardman 152
Helsinki 130
Bremen 119
Shanghai 116
New York 102
Jakarta 93
Council Bluffs 83
Redwood City 68
Milan 65
Rome 59
Guangzhou 48
Chicago 46
The Dalles 45
Bologna 44
Falls Church 40
Los Angeles 40
São Paulo 39
Norwalk 37
Dublin 34
Kilburn 34
Toronto 34
Munich 33
Fremont 32
Iasi 31
Nanjing 30
Seoul 29
Frankfurt am Main 27
Kunming 26
Jinan 22
Parma 22
Turku 22
Rio de Janeiro 21
Tokyo 21
Dong Ket 20
Des Moines 19
Fuzhou 19
Nuremberg 19
Brussels 18
Cortona 18
Melbourne 18
Amsterdam 17
San Mateo 17
Tashkent 17
Augusta 16
Nanchang 16
Prescot 16
Salt Lake City 16
San Francisco 16
Belo Horizonte 15
Chiswick 15
Olomouc 15
Fiorano Modenese 14
Paris 14
Boston 13
Brooklyn 13
Ankara 12
Auckland 12
Hounslow 12
Leawood 12
Naples 12
Phoenix 12
Stockholm 12
Tampa 12
Barcelona 11
Brasília 11
Jönköping 11
Reggio Emilia 11
Warsaw 11
Appignano 10
Dallas 10
Florence 10
Huddinge 10
Mountain View 10
Philadelphia 10
Totale 28.992
Salva come PNG Salva come JPEG
Nome #
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial 543
LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular Signalling 286
Anti-Mullerian hormone (AMH): what do we still need to know? 284
Vitamin D and ovarian reserve: making clinical decisions 277
The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH 255
Age-specific nomogram for the decline in antral follicle count throughout the reproductive period 248
FSHR polymorphism p.N680S mediates different responses to FSH in vitro 245
The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study 245
How Much Does AMH Really Vary in Normal Women? 243
Evidence for expression and functionality of FSH and LH/hCG receptors in human endometrium 243
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 242
Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH) 242
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 240
From a circle to a sphere: the ultrasound imaging of ovarian follicle with 2D and 3D technology 237
Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count 234
New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation 233
Embryo quality and implantation rate in two different culture media: ISM1 versus Universal IVF Medium. 232
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol 232
Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles 232
Chronic endometritis in recurrent implantation failure: Use of prednisone and IVF outcome 228
Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization 226
Elevated levels of nitrous dioxide are associated with lower AMH levels: A real-world analysis 226
MATER protein as substrate of PKCepsilon in human cumulus cells. 223
Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period 220
Reference values in ovarian response to controlled ovarian stimulation throughout the reproductive period 218
Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. 217
The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause 216
Adnexal Torsion during Pregnancy after Oocyte In Vitro Maturation and Intracytoplasmic Sperm Injection Cycle. 215
Nitric Oxide concentration in endometrial washing throughout the menstrual cycle 214
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction 214
Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles 214
Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study 210
Utero-vaginal anastomosis in the treatment of cervical atresia 210
Human ovarian tissue cryopreservation: effect of sucrose concentration on morphological features after thawing 209
Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study 209
The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro 209
Primary ovarian insufficiency: autoimmune causes. 208
A novel transnational fresh oocyte donation (TOD) program based on transport of frozen sperm and embryos 207
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice 206
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria 205
Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele 203
Periodontal disease and nitric oxide levels in low risk women with preterm labor 202
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 202
Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes 201
Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium 200
Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology 199
Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction 198
External validation of anti-Müllerian hormone based prediction of live birth in assisted conception 198
Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome? 197
A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles 195
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival 194
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome 193
The physiology and clinical utility of anti-Mullerian hormone in women 192
Thyroid function in early pregnancy II: Paradoxical growth hormone response to thyrotropin-releasing hormone 191
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome 190
The ovarian follicular pool and reproductive outcome in women. 189
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach 189
Surgical treatment of ovarian dermoid cysts 188
Perinatal outcomes following IVF with use of donor versus partner sperm 188
Rectovaginal fistula repair using fascia graft of autologous abdominal muscles 187
Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata 187
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia 187
Understanding the perceptions of and emotional barriers to infertility treatment: a survey in four European countries 187
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) 186
Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study 185
The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age 185
The management of vaginal agenesis: report of 104 cases 185
How to personalize ovarian stimulation in clinical practice 184
Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history 184
Insulin sensitizing agents and their effect on adrenal androgens?: the reply 184
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation 183
Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy 183
Possibilities and Limits of Ovarian Reserve Testing in ART 183
Basal progesterone level as the main determinant of progesterone elevation on the day of hCG triggering in controlled ovarian stimulation cycles 183
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients 182
Adrenal adenocarcinoma and empty sella syndrome in a 37-year-old woman 182
Reply: The two sides of the individualization of controlled ovarian stimulation 181
Short-term treatment of uterine fibromyomas with danazol 181
Advances in the Molecular Pathophysiology, Genetics, and Treatment of Primary Ovarian Insufficiency 181
Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women 181
Whatever its variability, antimüllerian hormone remains the most stable hormonal predictor 180
The use of ovarian reserve markers in IVF clinical practice: a national consensus 180
Hormonal and ultrasound markers of ovarian function in a woman with a balanced 1;11 translocation 179
Soluble L-selectin levels during controlled ovarian hyperstimulation 178
Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply 177
Anti-Müllerian hormone: clairvoyance or crystal clear? 177
Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome 177
Rectus abdominis muscle endometriosis: Case report and review of the literature 177
The role of ovarian suspension in endometriosis surgery: a randomized controlled trial 177
Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause 177
Recombinant human leptin in women with hypothalamic amenorrhea. 176
Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in PCOS patients 176
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome 175
Administration of L-thyroxine does not improve the response of the hypothalamo-pituitary-ovarian axis to clomiphene citrate in functional hypothalamic amenorrhea 175
Ultrastructural and DNA fragmentation analyses in swim-up selected human sperm 174
Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium 173
Thyroid function in early pregnancy I: Thyroid-stimulating hormone response to thyrotropin-releasing hormone 173
Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women 173
The FSHR polymorphism p.N680S mediates different response kinetics to FSH in vitro 173
8th World Congress of Gynecological Endocrinology 172
Totale 20.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 165.569
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 165.569
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020200 0 0 0 0 0 0 0 0 0 0 0 200
2020/20216.127 572 353 511 521 769 374 570 871 261 699 353 273
2021/20224.566 176 862 513 160 84 175 345 216 415 356 872 392
2022/20233.625 454 416 349 293 473 434 82 308 414 39 174 189
2023/20243.007 95 153 122 270 479 180 510 456 68 95 131 448
2024/20258.052 260 89 107 581 1.510 1.099 434 449 1.158 519 786 1.060
Totale 37.215